D-0265-2022 Class II Terminated

Recalled by Pfizer Inc. — New York, NY

FDA drug recall D-0265-2022 was initiated by Pfizer Inc. on Nov 30, 2021 and is designated Class II. Reason for recall: Lack of sterility assurance: bag has the potential to leak. The recall status is terminated (terminated Jul 12, 2023). Affected quantity: 765 bags.

Recall details

Product Type
Drugs
Report Date
Dec 8, 2021
Initiation Date
Nov 30, 2021
Termination Date
Jul 12, 2023
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
765 bags

Product description

5% Dextrose Injection, USP, 50 mL ADD-Vantage Unit, Rx only, Distributed by Hospira, INC., Lake Forest, IL 60045 USA, NDC 0409-7100-68/0409-7100-66

Reason for recall

Lack of sterility assurance: bag has the potential to leak.

Distribution pattern

USA Nationwide

Code information

Lot: 4923608 Exp. 1MAY2022

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0265-2022
openFDA file date
Nov 19, 2026
Loaded by RegDataLab
Nov 20, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Need the full FDA record for Pfizer Inc.? Ask Claude or ChatGPT with the RegDataLab connector and get every site's inspections, Form 483s, warning letters, recalls and import alerts, each with a link to the FDA source. The API key is free: no card.

Get a free API key

How the connector works

Source: openFDA record for D-0265-2022. Report a data issue: hello@regdatalab.com.